Literature DB >> 27627722

F11 rs2289252T and rs2036914C Polymorphisms Increase the Activity of Factor XI in Post-trauma Patients with Fractures Despite Thromboprophylaxis.

Nan Song1, Ai-Xian Tian2, Jian-Min Zhang2, Hong-Qiang Jiang2, Jia-Cheng Zang2, Xin-Long Ma2.   

Abstract

OBJECTIVE: To evaluate the association between F11 rs2289252, rs2036914 polymorphisms and the activity of clotting factor XI in post-trauma patients with fractures receiving routine anticoagulation therapy for deep venous thrombosis (DVT).
METHODS: A case-control study involving 110 consecutive post-trauma patients with fractures and DVT in our hospital was conducted from April 2014 to October 2015; these patients comprised a DVT group. Another 40 sex- and age-matched patients with fractures but without DVT served as controls. Additionally, 40 sex- and age-matched healthy people were chosen as a normal group. Venous blood samples (2 mL) were drawn from all participants and genomic DNA extracted from the leukocytes of the patients with fracture-related DVT, whose genotype and allele frequency distribution of F11 gene rs2089252 and rs2036914 single nucleotide polymorphism were then assessed by a sequencing method. The activity of factor XI was measured by a solidification method in all participants, including those in control and normal groups.
RESULTS: The activity of factor XI in patients with fracture-related DVT and F11 rs2089252 CT was 1.16 times that of those with CC genotypes (P < 0.0001), whereas in patients with fracture-related DVT and F11 rs2089252 TT genotypes it was 1.32 times that of those with CC genotypes (P < 0.0001), in patients with fracture-related DVT and F11 rs2089252 T allele it was 1.24 times that of those with C allele (P < 0.05), in patients with fracture-related DVT and F11 rs2036914 CC it was 1.35 times that of those with TT genotypes, in patients with fracture-related DVT and F11 rs2036914 CT genotypes it was 1.12 times that of those with TT genotypes (P < 0.05), and in patients with fracture-related DVT F11 and rs2036914 C allele it was 1.22 times that of those with T allele (P < 0.05). The activity of factor XI was significantly higher in the control than in the normal group (P < 0.05).
CONCLUSIONS: High activity of factor XI indicates a risk of occurrence of DVT in post-trauma patients with fractures. F11 rs2089252 and rs2036914 (single nucleotide polymorphisms) are associated with activity of factors XI in such patients despite prophylaxis.
© 2016 Chinese Orthopaedic Association and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Deep vein thrombosis; Factor XI; Fractures; Polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27627722      PMCID: PMC6584134          DOI: 10.1111/os.12262

Source DB:  PubMed          Journal:  Orthop Surg        ISSN: 1757-7853            Impact factor:   2.071


  25 in total

1.  Prophylaxis of deep-vein thrombosis after lower extremity amputation: comparison of low molecular weight heparin with unfractionated heparin.

Authors:  Sidney Lastória; Hamilton A Rollo; Winston Bonetti Yoshida; Mariangela Giannini; Regina Moura; Francisco H A Maffei
Journal:  Acta Cir Bras       Date:  2006-05-26       Impact factor: 1.388

2.  High levels of coagulation factor XI as a risk factor for venous thrombosis.

Authors:  J C Meijers; W L Tekelenburg; B N Bouma; R M Bertina; F R Rosendaal
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

3.  Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels.

Authors:  Giovanna Marchetti; Barbara Lunghi; Gianni Mazzoni; Michela Cini; Cristina Legnani; Francesco Bernardi
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249

Review 4.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis.

Authors:  James P Stannard; Robert R Lopez-Ben; David A Volgas; Edward R Anderson; Matt Busbee; Donna K Karr; Gerald R McGwin; Jorge E Alonso
Journal:  J Bone Joint Surg Am       Date:  2006-02       Impact factor: 5.284

6.  Prevention of venous thromboembolism after injury: an evidence-based report--part II: analysis of risk factors and evaluation of the role of vena caval filters.

Authors:  G C Velmahos; J Kern; L S Chan; D Oder; J A Murray; P Shekelle
Journal:  J Trauma       Date:  2000-07

Review 7.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Gene variants associated with deep vein thrombosis.

Authors:  Irene D Bezemer; Lance A Bare; Carine J M Doggen; Andre R Arellano; Carmen Tong; Charles M Rowland; Joseph Catanese; Bradford A Young; Pieter H Reitsma; James J Devlin; Frits R Rosendaal
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

9.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Genetic variants associated with deep vein thrombosis: the F11 locus.

Authors:  Y Li; I D Bezemer; C M Rowland; C H Tong; A R Arellano; J J Catanese; J J Devlin; P H Reitsma; L A Bare; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2009-07-06       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.